Target Product Profile for a Diagnostic Assay to Differentiate between Bacterial and Non-Bacterial Infections and Reduce Antimicrobial Overuse in Resource-Limited Settings: An Expert Consensus - PubMed (original) (raw)
. 2016 Aug 25;11(8):e0161721.
doi: 10.1371/journal.pone.0161721. eCollection 2016.
Birkneh Tilahun Tadesse 1 2 3, Francis Moussy 4, Arlene Chua 5, Anna Zorzet 6, Thomas Tängdén 6, David L Dolinger 1 4 5, Anne-Laure Page 7, John A Crump 8 9 10, Valerie D'Acremont 11 12, Quique Bassat 13 14, Yoel Lubell 15 16, Paul N Newton 15 17, Norbert Heinrich 18, Timothy J Rodwell 1, Iveth J González 1
Affiliations
- PMID: 27559728
- PMCID: PMC4999186
- DOI: 10.1371/journal.pone.0161721
Target Product Profile for a Diagnostic Assay to Differentiate between Bacterial and Non-Bacterial Infections and Reduce Antimicrobial Overuse in Resource-Limited Settings: An Expert Consensus
Sabine Dittrich et al. PLoS One. 2016.
Abstract
Acute fever is one of the most common presenting symptoms globally. In order to reduce the empiric use of antimicrobial drugs and improve outcomes, it is essential to improve diagnostic capabilities. In the absence of microbiology facilities in low-income settings, an assay to distinguish bacterial from non-bacterial causes would be a critical first step. To ensure that patient and market needs are met, the requirements of such a test should be specified in a target product profile (TPP). To identify minimal/optimal characteristics for a bacterial vs. non-bacterial fever test, experts from academia and international organizations with expertise in infectious diseases, diagnostic test development, laboratory medicine, global health, and health economics were convened. Proposed TPPs were reviewed by this working group, and consensus characteristics were defined. The working group defined non-severely ill, non-malaria infected children as the target population for the desired assay. To provide access to the most patients, the test should be deployable to community health centers and informal health settings, and staff should require <2 days of training to perform the assay. Further, given that the aim is to reduce inappropriate antimicrobial use as well as to deliver appropriate treatment for patients with bacterial infections, the group agreed on minimal diagnostic performance requirements of >90% and >80% for sensitivity and specificity, respectively. Other key characteristics, to account for the challenging environment at which the test is targeted, included: i) time-to-result <10 min (but maximally <2 hrs); ii) storage conditions at 0-40°C, ≤90% non-condensing humidity with a minimal shelf life of 12 months; iii) operational conditions of 5-40°C, ≤90% non-condensing humidity; and iv) minimal sample collection needs (50-100μL, capillary blood). This expert approach to define assay requirements for a bacterial vs. non-bacterial assay should guide product development, and enable targeted and timely efforts by industry partners and academic institutions.
Conflict of interest statement
The authors have declared that no competing interests exist.
Similar articles
- The future of Cochrane Neonatal.
Soll RF, Ovelman C, McGuire W. Soll RF, et al. Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834 - Optimising diagnosis of viraemic hepatitis C infection: the development of a target product profile.
Ivanova Reipold E, Easterbrook P, Trianni A, Panneer N, Krakower D, Ongarello S, Roberts T, Miller V, Denkinger C. Ivanova Reipold E, et al. BMC Infect Dis. 2017 Nov 1;17(Suppl 1):707. doi: 10.1186/s12879-017-2770-5. BMC Infect Dis. 2017. PMID: 29143620 Free PMC article. - Diagnosis and Treatment of the Febrile Child.
Herlihy JM, D’Acremont V, Hay Burgess DC, Hamer DH. Herlihy JM, et al. In: Black RE, Laxminarayan R, Temmerman M, Walker N, editors. Reproductive, Maternal, Newborn, and Child Health: Disease Control Priorities, Third Edition (Volume 2). Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2016 Apr 5. Chapter 8. In: Black RE, Laxminarayan R, Temmerman M, Walker N, editors. Reproductive, Maternal, Newborn, and Child Health: Disease Control Priorities, Third Edition (Volume 2). Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2016 Apr 5. Chapter 8. PMID: 27227231 Free Books & Documents. Review. - [Diagnostic kits in parasitology: which controls?].
Rossi P. Rossi P. Parassitologia. 2004 Jun;46(1-2):145-9. Parassitologia. 2004. PMID: 15305705 Review. Italian. - Host Biomarkers for Distinguishing Bacterial from Non-Bacterial Causes of Acute Febrile Illness: A Comprehensive Review.
Kapasi AJ, Dittrich S, González IJ, Rodwell TC. Kapasi AJ, et al. PLoS One. 2016 Aug 3;11(8):e0160278. doi: 10.1371/journal.pone.0160278. eCollection 2016. PLoS One. 2016. PMID: 27486746 Free PMC article. Review.
Cited by
- Point-of-Care Biomarkers to Guide Antibiotic Prescription for Acute Febrile Illness in Sub-Saharan Africa: Promises and Caveats.
van Griensven J, Cnops L, De Weggheleire A, Declercq S, Bottieau E. van Griensven J, et al. Open Forum Infect Dis. 2020 Jun 30;7(8):ofaa260. doi: 10.1093/ofid/ofaa260. eCollection 2020 Aug. Open Forum Infect Dis. 2020. PMID: 32818139 Free PMC article. Review. - Two-test algorithms for infectious disease diagnosis: Implications for COVID-19.
Pokharel S, White LJ, Sacks JA, Escadafal C, Toporowski A, Mohammed SI, Abera SC, Kao K, Melo Freitas M, Dittrich S. Pokharel S, et al. PLOS Glob Public Health. 2022 Mar 31;2(3):e0000293. doi: 10.1371/journal.pgph.0000293. eCollection 2022. PLOS Glob Public Health. 2022. PMID: 36962160 Free PMC article. - Development of a target product profile for new glucose self-monitoring technologies for use in low- and middle-income countries.
Safary E, Lepeska M, Beran D, Ewen M, Zhaparova A, Rukare J, Boulle P, Aebischer Perone S, Makohliso S, Pleus S, Vetter B. Safary E, et al. PLoS One. 2024 Aug 26;19(8):e0309062. doi: 10.1371/journal.pone.0309062. eCollection 2024. PLoS One. 2024. PMID: 39186719 Free PMC article. - Target Product Profiles for medical tests: a systematic review of current methods.
Cocco P, Ayaz-Shah A, Messenger MP, West RM, Shinkins B. Cocco P, et al. BMC Med. 2020 May 11;18(1):119. doi: 10.1186/s12916-020-01582-1. BMC Med. 2020. PMID: 32389127 Free PMC article. - Febrile Illness Evaluation in a Broad Range of Endemicities (FIEBRE): protocol for a multisite prospective observational study of the causes of fever in Africa and Asia.
Hopkins H, Bassat Q, Chandler CI, Crump JA, Feasey NA, Ferrand RA, Kranzer K, Lalloo DG, Mayxay M, Newton PN, Mabey D; FIEBRE Consortium. Hopkins H, et al. BMJ Open. 2020 Jul 21;10(7):e035632. doi: 10.1136/bmjopen-2019-035632. BMJ Open. 2020. PMID: 32699131 Free PMC article.
References
- Farrar J HP, Junghanss T, Kang G, Lalloo D, White NJ. Manson's Tropical Diseases. 22nd Edition ed. London, UK: Saunders; 2009.
- Lubell Y, Althaus T, Blacksell SD, Paris DH, Mayxay M, Pan-Ngum W, et al. Modelling the Impact and Cost-Effectiveness of Biomarker Tests as Compared with Pathogen-Specific Diagnostics in the Management of Undifferentiated Fever in Remote Tropical Settings. PloS one. 2016;11(3):e0152420 Epub 2016/03/31. 10.1371/journal.pone.0152420 - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous